Robert Fried

And that ended up taking much more of my time.

And by the 2000s, I was marginally involved in movies.

But I was interested in aging.

I was a young man at that time, and I had met an investor who was investing actually in telomeres.

And at that time, in the late 90s and the early 2000s, the state-of-the-art research on anti-aging science was telomeres starting to pivot to something called sirtuins.

These were all the people researching, and I just found it interesting.

And that interest became a passion, became actually a series of investments, and ultimately became this.

So my pivot from Hollywood to this was not like a nonstop flight.

It was a series of opportunities and chances and interests that one thing led to another.

And before you know it, I was here.

Hmm.

And so for how many years would you say have you been steeped in this sort of anti-aging longevity space?

I've been a student of it since 1998.

Wow.

And I started investing in various companies, including that telomere company in 2000.

And then another in the 2000s, Chromadex.

Niagen Bioscience used to be called Chromadex.

I began buying Chromadex stock in 2013 and went on the board in 2015 and became the CEO in 2018.

And what was that moment for you?

Because you obviously had had at that point exposure to all of these really novel and I would guess really impressive ideas in the longevity space, sirtuins, telomeres.